Compare $APUS vs $LGVN | Chartloom

Compare

$APUS vs $LGVN

Apimeds Pharmaceuticals US Inc · Longeveron Inc

APUS

Apimeds Pharmaceuticals US Inc

LGVN

Longeveron Inc

Compare $APUS vs $LGVN

Comparing Apimeds Pharmaceuticals US Inc and Longeveron Inc

APUSApimeds Pharmaceuticals US Inc

LGVNLongeveron Inc

APUSApimeds Pharmaceuticals US Inc

Market cap

$8M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-69.8%

52W performance

-75.9%

FCF yield

-70.6%

LGVNLongeveron Inc

Market cap

$78M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

64.70x

Rev growth (TTM)

-42.7%

YTD performance

-58.2%

52W performance

-73.3%

FCF yield

-26.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

APUS

LGVN

Detailed metrics comparison

APUS

Apimeds Pharmaceuticals US Inc

LGVN

Longeveron Inc

Market Cap

APUS$8M

LGVN$78M

Enterprise Value

APUS$22M

LGVN$68M

Price

APUS$5.02

LGVN$2.48

P/E Ratio

APUSN/A

LGVNN/A

P/S Ratio

APUS0.00x

LGVN66.02x

EV/Sales

APUS0.00x

LGVN57.53x

EV/EBITDA

APUS0.00x

LGVN0.00x

P/B Ratio

APUS0.05x

LGVN0.79x

P/FCF Ratio

APUSN/A

LGVNN/A

EV/FCF

APUS-4.06x

LGVN-3.30x

PEG Ratio

APUSN/A

LGVNN/A

Forward P/E (NTM)

APUSN/A

LGVNN/A

Forward P/S (NTM)

APUSN/A

LGVN64.70x

Revenue (TTM)

APUS$0

LGVN$1M

Revenue Growth (YoY)

APUSN/A

LGVN-42.7%

Forward Rev Growth

APUS0.0%

LGVN398.7%

Gross Margin (TTM)

APUS0.0%

LGVN69.8%

Operating Margin (TTM)

APUS0.0%

LGVN0.0%

EBITDA Margin (TTM)

APUS0.0%

LGVN-1907.3%

Net Margin (TTM)

APUS0.0%

LGVN-1977.6%

FCF Margin (TTM)

APUSN/A

LGVN-1742.1%

Net Income (TTM)

APUS$-58M

LGVN$-23M

FCF (TTM)

APUS$-5M

LGVN$-21M

EPS (TTM)

APUS-$33.95

LGVN-$7.48

ROE (TTM)

APUS-5898.0%

LGVN-22319.0%

ROA (TTM)

APUS-5261.0%

LGVN-15020.0%

ROIC (TTM)

APUS-5458.0%

LGVN-22319.0%

Cash

APUS$278K

LGVN$10M

Debt

APUS$14M

LGVN$0

Net Cash/Debt

APUS$-14M

LGVN$10M

Current Ratio (TTM)

APUS0.51x

LGVN2.63x

Quick Ratio (TTM)

APUS0.40x

LGVN2.35x

Debt/Equity (TTM)

APUS0.14x

LGVN0.00x

Debt/Assets (TTM)

APUS0.0%

LGVN0.0%

Interest Coverage (TTM)

APUSN/A

LGVNN/A

Net Debt/EBITDA (TTM)

APUS0.00x

LGVN0.00x

Beta

APUS2.60

LGVN0.85

52W Performance

APUS-75.9%

LGVN-73.3%

YTD Performance

APUS-69.8%

LGVN-58.2%

% from 52W High

APUS-91.6%

LGVN-79.8%

% from 52W Low

APUS232.5%

LGVN7.8%

Asset Turnover (TTM)

APUS0.00x

LGVN0.08x

FCF Yield (TTM)

APUS-70.6%

LGVN-26.4%

Earnings Yield (TTM)

APUS-767.4%

LGVN-30.0%

Dividend Yield (TTM)

APUSN/A

LGVNN/A

Rule of 40

APUS0.0

LGVN-1,784.9

EV/GP/RG

APUSN/A

LGVN40.37

Ticker research

View APUS research View LGVN research

Metric	APUS Apimeds Pharmaceuticals US Inc	LGVN Longeveron Inc
Market & Valuation
Market Cap	$8M	$78M
Enterprise Value	$22M	$68M
Price	$5.02	$2.48
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	66.02x
EV/Sales	0.00x	57.53x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.05x	0.79x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.06x	-3.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	64.70x
Revenue & Growth
Revenue (TTM)	$0	$1M
Revenue Growth (YoY)	N/A	-42.7%
Forward Rev Growth	0.0%	398.7%
Profitability
Gross Margin (TTM)	0.0%	69.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1907.3%
Net Margin (TTM)	0.0%	-1977.6%
FCF Margin (TTM)	N/A	-1742.1%
Net Income (TTM)	$-58M	$-23M
FCF (TTM)	$-5M	$-21M
EPS (TTM)	-$33.95	-$7.48
ROE (TTM)	-5898.0%	-22319.0%
ROA (TTM)	-5261.0%	-15020.0%
ROIC (TTM)	-5458.0%	-22319.0%
Financial Health
Cash	$278K	$10M
Debt	$14M	$0
Net Cash/Debt	$-14M	$10M
Current Ratio (TTM)	0.51x	2.63x
Quick Ratio (TTM)	0.40x	2.35x
Debt/Equity (TTM)	0.14x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.60	0.85
52W Performance	-75.9%	-73.3%
YTD Performance	-69.8%	-58.2%
% from 52W High	-91.6%	-79.8%
% from 52W Low	232.5%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.08x
FCF Yield (TTM)	-70.6%	-26.4%
Earnings Yield (TTM)	-767.4%	-30.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,784.9
EV/GP/RG	N/A	40.37
Ticker research	View APUS research	View LGVN research

Valuation

P/S Ratio

APUS

0.00x

LGVN

66.02x

EV/FCF

APUS

-4.06x

LGVN

-3.30x

Growth & revenue

Revenue Growth TTM

LGVN

-42.7%

Forward Revenue Growth

LGVN

398.7%

APUS

0.0%

Profitability & performance

Gross Margin

LGVN

69.8%

APUS

0.0%

ROE

APUS

-5898.0%

LGVN

-22319.0%

FCF Yield %

LGVN

-26.4%

APUS

-70.6%

52-Week Performance

LGVN

-73.3%

APUS

-75.9%

Detailed metrics comparison

APUS

Apimeds Pharmaceuticals US Inc

LGVN

Longeveron Inc

Market Cap

APUS$8M

LGVN$78M

Enterprise Value

APUS$22M

LGVN$68M

Price

APUS$5.02

LGVN$2.48

P/E Ratio

APUSN/A

LGVNN/A

P/S Ratio

APUS0.00x

LGVN66.02x

EV/Sales

APUS0.00x

LGVN57.53x

EV/EBITDA

APUS0.00x

LGVN0.00x

P/B Ratio

APUS0.05x

LGVN0.79x

P/FCF Ratio

APUSN/A

LGVNN/A

EV/FCF

APUS-4.06x

LGVN-3.30x

PEG Ratio

APUSN/A

LGVNN/A

Forward P/E (NTM)

APUSN/A

LGVNN/A

Forward P/S (NTM)

APUSN/A

LGVN64.70x

Revenue (TTM)

APUS$0

LGVN$1M

Revenue Growth (YoY)

APUSN/A

LGVN-42.7%

Forward Rev Growth

APUS0.0%

LGVN398.7%

Gross Margin (TTM)

APUS0.0%

LGVN69.8%

Operating Margin (TTM)

APUS0.0%

LGVN0.0%

EBITDA Margin (TTM)

APUS0.0%

LGVN-1907.3%

Net Margin (TTM)

APUS0.0%

LGVN-1977.6%

FCF Margin (TTM)

APUSN/A

LGVN-1742.1%

Net Income (TTM)

APUS$-58M

LGVN$-23M

FCF (TTM)

APUS$-5M

LGVN$-21M

EPS (TTM)

APUS-$33.95

LGVN-$7.48

ROE (TTM)

APUS-5898.0%

LGVN-22319.0%

ROA (TTM)

APUS-5261.0%

LGVN-15020.0%

ROIC (TTM)

APUS-5458.0%

LGVN-22319.0%

Cash

APUS$278K

LGVN$10M

Debt

APUS$14M

LGVN$0

Net Cash/Debt

APUS$-14M

LGVN$10M

Current Ratio (TTM)

APUS0.51x

LGVN2.63x

Quick Ratio (TTM)

APUS0.40x

LGVN2.35x

Debt/Equity (TTM)

APUS0.14x

LGVN0.00x

Debt/Assets (TTM)

APUS0.0%

LGVN0.0%

Interest Coverage (TTM)

APUSN/A

LGVNN/A

Net Debt/EBITDA (TTM)

APUS0.00x

LGVN0.00x

Beta

APUS2.60

LGVN0.85

52W Performance

APUS-75.9%

LGVN-73.3%

YTD Performance

APUS-69.8%

LGVN-58.2%

% from 52W High

APUS-91.6%

LGVN-79.8%

% from 52W Low

APUS232.5%

LGVN7.8%

Asset Turnover (TTM)

APUS0.00x

LGVN0.08x

FCF Yield (TTM)

APUS-70.6%

LGVN-26.4%

Earnings Yield (TTM)

APUS-767.4%

LGVN-30.0%

Dividend Yield (TTM)

APUSN/A

LGVNN/A

Rule of 40

APUS0.0

LGVN-1,784.9

EV/GP/RG

APUSN/A

LGVN40.37

Ticker research

View APUS research View LGVN research

Metric	APUS Apimeds Pharmaceuticals US Inc	LGVN Longeveron Inc
Market & Valuation
Market Cap	$8M	$78M
Enterprise Value	$22M	$68M
Price	$5.02	$2.48
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	66.02x
EV/Sales	0.00x	57.53x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.05x	0.79x
P/FCF Ratio	N/A	N/A
EV/FCF	-4.06x	-3.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	64.70x
Revenue & Growth
Revenue (TTM)	$0	$1M
Revenue Growth (YoY)	N/A	-42.7%
Forward Rev Growth	0.0%	398.7%
Profitability
Gross Margin (TTM)	0.0%	69.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1907.3%
Net Margin (TTM)	0.0%	-1977.6%
FCF Margin (TTM)	N/A	-1742.1%
Net Income (TTM)	$-58M	$-23M
FCF (TTM)	$-5M	$-21M
EPS (TTM)	-$33.95	-$7.48
ROE (TTM)	-5898.0%	-22319.0%
ROA (TTM)	-5261.0%	-15020.0%
ROIC (TTM)	-5458.0%	-22319.0%
Financial Health
Cash	$278K	$10M
Debt	$14M	$0
Net Cash/Debt	$-14M	$10M
Current Ratio (TTM)	0.51x	2.63x
Quick Ratio (TTM)	0.40x	2.35x
Debt/Equity (TTM)	0.14x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.60	0.85
52W Performance	-75.9%	-73.3%
YTD Performance	-69.8%	-58.2%
% from 52W High	-91.6%	-79.8%
% from 52W Low	232.5%	7.8%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.08x
FCF Yield (TTM)	-70.6%	-26.4%
Earnings Yield (TTM)	-767.4%	-30.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,784.9
EV/GP/RG	N/A	40.37
Ticker research	View APUS research	View LGVN research